The U.S. Food and Drug Administration has given 510(k) clearance to the company’s SOLX 790 for use in Titanium: Sapphire laser trabeculoplasty (TLT). The clearance followed the results of a multi-center clinical trial which established the equivalence of TLT to ALT in its ability to reduce intraocular pressure (IOP) in patients suffering from primary open angle glaucoma and poorly controlled IOP. The laser emits pulses of energy at a wavelength of 790 nm that loosens particles in the trabecular meshwork. The penetration of this energy into the tissue is deeper than other currently used trabeculoplasty lasers. The treatment is long-lasting and less damaging.